welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051
The U.S. Food and Drug Administration has taken a step that will allow Sarepta Therapeutics to start clinical trials of its Duchenne muscular dystrophy therapy SRP-5051.
That move was accepting the company’s Investigational New Drug application for SRP-5051. The therapy, known as a peptide phosphorodiamidate morpholino oligomer, is designed to treat those whose Duchenne MD stems from the exon 51 genetic mutation. They constitute the largest group of DMD patients — about 13 percent.
Genes are made up of dozens of components known as exons. A missing exon can lead to a gene mutation that generates a faulty protein, causing a disease.
rareRelated
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
-
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy who Participated in Studies of SRP-5051The purpose of this extension study is t...
-
Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular DystrophySarepta Therapeutics, Inc., the leader...
-
ICER Releases Draft Evidence Report on Treatments for Duchenne Muscular DystrophyThe Institute for Clinical and Economic ...
-
AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 DuplicationsOpen-label, single dose clinical trial o...
-
Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for ...Audentes Therapeutics, Inc., a leading A...
-
Insurers battle families over costly drug for fatal diseaseNolan and Jack Willis, twins from upstat...
-
ICER Document Reviews Effectiveness of 3 Duchenne MD TherapiesThe Institute for Clinical and Economic ...
